In 2015, introduction of a disease staging system offered a framework for benchmarking progression to clinical type 1 ...
The 2021 approval by regulatory agencies of belimumab, a B lymphocyte stimulator (BLyS) inhibitor, and the 2022 approval of anifrolumab, a type I interferon inhibitor, has increased the therapeutic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback